Aratana Therapeutics
Aratana Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for dogs and cats in the United States. Founded in 2010 and headquartered in Leawood, Kansas, the company focuses on addressing unmet medical needs in companion animal care through high-quality medicines. Its product portfolio includes various therapeutics, such as NOCITA for post-operative pain management in dogs, ENTYCE for appetite stimulation, and GALLIPRANT for pain and inflammation associated with osteoarthritis. Aratana is also advancing treatments for conditions like osteosarcoma in dogs and a range of therapies for cats, including a specialized formulation for pain management and treatments for feline herpes virus-induced conditions. The company has established collaboration agreements with other health organizations to enhance the development and commercialization of its products.
Okapi Sciences
Acquisition in 2014
Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics for pets and livestock. It operates a proprietary platform dedicated to creating innovative treatments for significant viral diseases, with five candidates currently in clinical or development stages. The company specializes in addressing viral infections affecting pets, particularly through its work on feline herpes and feline immunodeficiency virus. Okapi Sciences is committed to advancing its pipeline of antiviral drugs while fostering strong relationships with academic institutions to enhance its research capabilities and technological advancements in veterinary medicine.
Vet Therapeutics
Acquisition in 2013
Vet Therapeutics is developing antibody-based therapies to treat pet cancer and chronic conditions. The company is committed to bringing the same modality of products that constitute the standard of care in humans to animal health by applying world-class science to new products for companion animals. The Vet Therapeutics team has more than 30 years' experience and a successful track record at developing antibody-based biologics for humans, which is directed towards the development of pet-specific biologics to treat pet cancer and chronic conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.